RAAS
RAAS
RAAS the company has been adhering to the quality policy
RAAS was founded in 1988 and listed on the Shenzhen Stock Exchange in 2008 (stock code: 002252), is a leading blood products company in Asia. Since its establishment 28 years ago, the company has been adhering to the quality policy of "safety, quality and efficiency", and has developed 11 products covering three categories of blood products: human blood protein, human immunoglobulin and coagulation factors, including human albumin, human immunoglobulin, static human immunoglobulin, hepatitis B human immunoglobulin, tetanus toxoid, and human immunoglobulin. Human immunoglobulin, rabies human immunoglobulin, human prothrombin complex, human coagulation factor VIII, lyophilized human thrombin, human fibrinogen, topical lyophilized human fibrin binder. Shanghai RAAS has been registered in nearly 20 countries, and is one of the few domestic manufacturers that can export blood products. Up to now, Shanghai RAAS has 33 plasma stations in China including those under construction, with an annual production capacity of 900 tons of plasma and more than 25 million vials of blood products.
- All
- News
- Analysis
- Research
Briefing Sep 21, 2022 10:38 AM
· Healthcare
Weiyou Gene Nets Tens of Millions of CNY in Series Pre-A Round
Briefing Sep 16, 2022 11:10 PM
· Healthcare
NaviSeed Nets Tens of millions of CNY in Angel Round
In-depth
Healthcare
Immunotherapy in China: A Rising Star in the Field of Cancer Treatment
Immunotherapy is emerging as a powerful weapon in fighting cancer by restarting and maintaining the cancer-immunity cycle to identify, control and eliminate tumor cells rather than killing them directly.
Nov 24, 2022 06:29 PM
Briefing Sep 13, 2022 05:30 PM
· Healthcare
Nuwacell Nets Hundreds of Mns of CNY in Series A
Briefing Aug 31, 2022 08:30 PM
· Healthcare
Enitiatebio Nets One Hundred Million of CNY in Series A Round
Nov 16, 2022 05:19 PM
Nov 07, 2022 04:27 PM
Aug 29, 2022 05:45 PM
Apr 22, 2021 03:11 PM
Briefing Jun 28, 2022 09:56 AM
· Healthcare
And platinum medicine b7h4x4-1bb bispecific antibody were approved by FDA for new drug research
Briefing Jun 28, 2022 09:54 AM
· Healthcare
Fosun pharma and Amgen have reached cooperation to accelerate the commercialization of two innovative drugs in China
Briefing Jun 28, 2022 09:50 AM
· Healthcare
It is expected to achieve functional cure of chronic hepatitis B! GSK antisense therapy phase IIB positive clinical results
Briefing Jun 28, 2022 09:37 AM
· Healthcare
Aibo biology: cooperate with Jiahe biology to jointly develop tumor mRNA drugs
Briefing Dec 02, 2021 08:29 PM
· Financials
Shanghai Laishi: Kerui Tiancheng investment holding has passively reduced its stake of 2.09%
Insight
Healthcare
15 Companies to Watch in November 2022-Healthcare
Editor's note: We at EqualOcean tracked the major funding rounds or industry events that took place in China's healthcare space in November 2022. And the following is a list of deals that we have selected for you, based on a number of criteria, including the funding amount, the financial backers, and the segments in which the startups operate.
Dec 01, 2022 06:02 PM
Briefing Oct 13, 2021 06:53 PM
· Consumer Staples
Shanghai Laishi: Laishi China plans to passively reduce its holdings of no more than 10.24 million shares
Briefing Sep 08, 2021 08:43 PM
Shanghai Laishi: the controlling shareholder and actual controller are changed to none
Briefing Aug 13, 2021 08:13 PM
· Technology
Shanghai Laishi: Kerui Tiancheng and those acting in concert have passively reduced 672 million shares
See more
Related Companies
EqualOcean Analysis